

Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC).

**Authors:**

Laura Toppo, Wanda Liguigli, Chiara Senti, Gianluca Tomasello, Michele Ghidini, Margherita Ratti, Andrea Botticelli, Concetta Elisa Onesti, Francesca Di Pietro, Claudio Pizzo, Stefano Panni, Alessandra Curti, Rodolfo Passalacqua; Oncology Unit, ASST Cremona, Cremona, Italy; Department of Clinical and Molecular Medicine, Sapienza University Sant' Andrea Hospital, Rome, Italy

**Abstract Disclosures**

**Background:**

The presence of BM in AGC is a relatively uncommon finding and has a poor prognosis [Leporini C. 2015]. At diagnosis the presence of BM occurs in approximately 10-15% of pts with AGC.[Park 2011; Silvestris 2013]. Aim of this study is to describe the main features of pts with AGC and BM at diagnosis and the prognostic implications.

**Methods:**

A consecutive series of AGC followed at Cremona Oncology Division from November 2004 to December 2016 and included in three consecutive prospective trials [Dalla Chiesa M. 2011; Tomasello G. 2013], were analyzed. All pts were treated with a modified DCF (docetaxel, cisplatin, fluorouracil) given as a dose-dense regimen, every 14 days. We analyzed pts with BM at diagnosis (BMaD) and pts without BMaD. We evaluated baseline clinical and pathological parameters, the presence of coagulation disorders (CD) together with efficacy measures in the two groups.

**Results:**

218 pts with AGC were identified (38 with BMaD and 180 without BMaD).Main pts characteristics and results are reported in the Table below.

**Conclusions:**

The presence of BM at diagnosis in pts with AGC is not a rare event (21%) and identifies a population with a significantly poorer outcome and a higher incidence of CD, that need a clinical monitoring of coagulation parameters. More efforts are required to understand the reasons of the different prognosis and to find specific treatments to improve the survival.

**Pts characteristics and results.**

Parameter	No BM (N=180)	BM (N=38)	P value
<b>Age, median</b>	65	62	0.2
<b>Sex: M/F (%)</b>	73/27	81/19	0.29
<b>PS 0-1-2 (%)</b>	52-42-6	42-37-18	0.11
<b>Mets sites &gt;2</b>	29/180 (16%)	26/36 (72%)	0.01
<b>DCR</b>	81%	63%	0.002
<b>PFS, median (95%IC)</b>	7.8 (6.7-9.3)	5.2 (2.5-7.1)	<0.001
<b>OS median (95%IC)</b>	13.1 (10.9-15)	7.0 (5.8-9.0)	<0.001
<b>CD</b>	1/180 (0.6%)*	7/28 (25%)**	<0.001

DCR: Disease Control Rate. OS: Overall Survival; PFS: Progression Free Survival. Coagulation Disorders (CD) = \*DIC Disseminated Intravascular Coagulation 1 pt; \*\*DIC 5 pts, Thrombotic Thrombocytopenic Purpura 1pt, and Moskowitz Syndrome 1 pt

